Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Trial Profile

A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs RRx 001 (Primary) ; Cisplatin
  • Indications Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms PREVLAR
  • Sponsors EpicentRx
  • Most Recent Events

    • 26 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 07 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jun 2018.
    • 07 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top